Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)
Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité - Universitätsmedizin Berlin
-
Berlin, Germany
- Neurologische Praxis
-
Berlin, Germany
- Neurologisches Facharztzentrum
-
Halle, Germany
- Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Potsdam, Germany
- Sankt Josefs Krankenhaus Potsdam Neurologie
-
-
Brandenburg
-
Teupitz, Brandenburg, Germany
- Kliniken für Neurologie Teupitz/Lübben, Asklepios Fachkliniken Brandenburg GmbH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent
- Age between 18 and 65 at randomization
- Relapsing-remitting MS according to the revised McDonald-Criteria (2005)
- EDSS ≤ 6,0
- Stable immunomodulatory treatment for at least 3 months
- Sufficient birth control (Pearl-Index <1) and negative pregnancy test at screening/randomization
Exclusion Criteria:
- Any other MS-course than RRMS
- Treatment with high dose vitamin D within 6 months prior to randomization
- Patients who have received over the last three months prior to randomization, an immunomodulatory therapy with the exception of IFN-β1b (Betaferon ®)
- Any condition that could interfere with MRI or other study related investigation
- Intolerability to Gd-DTPA
- Hypersensitivity to the drug Colecalciferol
- Patients with sarcoidosis
- Presence or history of nephrolithiasis
- Pseudohypoparathyroidism
Clinically relevant dysfunction of liver, bone narrow or kidney defined by the following laboratory values:
- HB <8.5 g / dl
- WBC <2.5 / nl
- platelet count <100/nl
- Creatinine clearance by Cockcroft-Gault formula: Cl <110ml/min (male) and Cl <95ml/min (female)
- AST / ALT> 3.5 times higher than the upper reference value
- bilirubin> 2.0 mg / dl
- hypercalcaemia> 2.7 mmol / l
- calcium / creatinine ratio in urine> 1
- Treatment with hydrochlorothiazide, digitoxin, digoxin, phenytoin, barbiturates
- Pregnancy or lactation period
- Participation in any clinical study within 3 months before or at any time during study
- Any medical, psychiatric or other condition that could interfere with the patient's ability to understand and give the informed consent, to comply with the protocol or to finish the study any ruling commitment or placement in an institution
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Verum (high dose)
verum arm receiving high dose Vitamin D oil
|
oil: 20000 IU/g tablet: 400 IU/g every second day
|
|
Experimental: Verum (low dose)
low dose arm receiving neutral oil and low dose of Vitamin D
|
neutral oil and a low dose of vitamin D
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy parameters
Time Frame: 1 day
|
efficacy of Vitamin D (high dose) in patients with Multiple Sclerosis compared to low dose of Vitamin D
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety & tolerability parameters
Time Frame: 1 day
|
Routine laboratory, vital signs, physical examination, ECG, AE reporting, Quality of Life
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Jan-Markus Dörr, Dr., Charité
- Principal Investigator: Jan-Markus Dörr, Dr., Charite-NeuroCure
Publications and helpful links
General Publications
- Backer-Koduah P, Infante-Duarte C, Ivaldi F, Uccelli A, Bellmann-Strobl J, Wernecke KD, Sy M, Demetriou M, Dorr J, Paul F, Ulrich Brandt A. Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS. Ann Clin Transl Neurol. 2020 Sep;7(9):1628-1641. doi: 10.1002/acn3.51148. Epub 2020 Aug 23.
- Dorr J, Backer-Koduah P, Wernecke KD, Becker E, Hoffmann F, Faiss J, Brockmeier B, Hoffmann O, Anvari K, Wuerfel J, Piper SK, Bellmann-Strobl J, Brandt AU, Paul F. High-dose vitamin D supplementation in multiple sclerosis - results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. Mult Scler J Exp Transl Clin. 2020 Jan 24;6(1):2055217320903474. doi: 10.1177/2055217320903474. eCollection 2020 Jan-Mar.
- Dorr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials. 2012 Feb 8;13:15. doi: 10.1186/1745-6215-13-15.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Micronutrients
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
- Vitamins
- Ergocalciferols
Other Study ID Numbers
Other Study ID Numbers
- EVIDIMS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.